![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, March 22, 2016 6:54:43 PM
Copied and pasted an excerpt as posted on another message board...
SHOW TIME AT OPKO FORBES
New products and FDA approvals. These are two key factors investors should focus on before putting their trust and money in a biopharma or biotech company, particularly the young ones. And some savvy investors may have spotted such an opportunity with OPKO Health, Inc. (OPK). a diversified drug and medical diagnostics company, with its own significant proprietary drug portfolio.
The reason: One of OPKO’s major drugs, Rayaldee, an oral vitamin D treatment aimed at people suffering from chronic kidney disease, is expected to be approved by the Food and Drug Administration by the end of March.
The expectation for the approval is based on OPKO’s obtaining recently a PDUFA (Prescription Drug User Fee Act) dated March 29, 2016. The PDUFA date represents the deadline for the FDA to approve a new drug. As a result, Wall Street analysts have been effusive in their positive comments about OPKO and its stock. Chronic kidney disease afflicts more than 26 million people in the U.S. alone, according to the National Kidney foundation. Driving the worldwide spread of chronic kidney disease in developed countries are an aging population and the growing problem of obesity.
“The upcoming Rayaldee PDUFA represents the new major catalyst for OPKO,” says Dana Flanders, equity analyst at J.P. Morgan Securities, who rates the stock, currently trading a $11.59 a share, as “overweight.” The analyst notes that OPKO has held labeling discussions with the FDA, and that the company is now researching product pricing, manufacturing preparations and inventory, as well as key hiring of sales representatives for Rayaldee’s launch.
Flanders sees Rayaldee as a “meaningful growth driver” for OPKO and forecasts sales reaching about $500 million by 2025. To demonstrate how big a product Rayaldee could be, that $500 million figure is more than OPKO’s consolidated revenues for all of 2015.
Recent OPK News
- NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner • PR Newswire (US) • 07/02/2024 12:00:00 PM
- OPKO Health to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/31/2024 02:48:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:29:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:07:44 PM
- OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 09:02:37 PM
- AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • GlobeNewswire Inc. • 03/05/2024 01:52:22 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 09:05:23 PM
- NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st • PR Newswire (US) • 02/28/2024 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:07:54 PM
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/16/2024 09:53:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:07:24 PM
- NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China • PR Newswire (US) • 02/05/2024 01:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 08:30:14 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:09:07 PM
- OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes • GlobeNewswire Inc. • 01/09/2024 09:05:28 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM